Macro Finance
Roche’s Second-Quarter Sales Held Back by Blockbuster Eye Drug
Bloomberg Markets·July 23, 2026·1 min read
Roche Holding's second-quarter sales were held back by a slower-than-expected recovery for its blockbuster eye drug Vabysmo. Investors are now looking to a key new drug to power future growth. The results disappointed analysts who had anticipated a stronger rebound for the drug, which faces competition in the wet age-related macular degeneration market.
Read at Bloomberg MarketsDaily crypto arcade
Read the news, then play it.
Chainshorts turns crypto headlines into a daily game. Catch up in 60 words, then jump into daily lucky draws for a shot at the pot.